ライフサイエンスコーパス: combined immunodeficiency

1 capsules of SCID mice (ie, mice with severe combined immunodeficiency).

2 h protection occurred without causing severe combined immunodeficiency.

3 erize an inflammatory disease evocative of a combined immunodeficiency.

4 ations associated with multiple atresia with combined immunodeficiency.

5 ncy is a rare, but life-threatening, primary combined immunodeficiency.

6 mbined immunodeficiency, Omenn syndrome, and combined immunodeficiency.

7 tenuated MM tumor growth in mice with severe combined immunodeficiency.

8 who displayed an unusual progressive form of combined immunodeficiency.

9 inflammatory bowel disease-like disorder and combined immunodeficiency.

10 s with gene therapy for ADA-deficient severe combined immunodeficiency.

11 esting conditions in mice and a patient with combined immunodeficiency.

12 1-null mutant mice on a background of severe combined immunodeficiency.

13 myelokathexis (WHIM) syndrome, a human rare combined immunodeficiency.

14 idered LCK a candidate gene in patients with combined immunodeficiency.

15 rigel, and formed tumors in mice with severe combined immunodeficiency.

16 assays in nonobese diabetic mice with severe combined immunodeficiency.

17 ch is mutated in humans with X-linked severe combined immunodeficiency.

18 subsequently received a diagnosis of severe combined immunodeficiency.

19 ciency is associated with a novel variant of combined immunodeficiency.

20 vels of IgE are features of some variants of combined immunodeficiency.

21 1 leads to a severe clinical presentation of combined immunodeficiency.

22 ns and null mutations in mice lead to severe combined immunodeficiency.

23 om 9 patients with genetically confirmed PNP-combined immunodeficiency, 10,000 DBS samples from healt

24 4%) an autoinflammatory disorder, 14 (15%) a combined immunodeficiency, 3 (3%) an innate immune defec

25 ated in human radiosensitive T(-)B(-) severe combined immunodeficiency, a syndrome characterized by t

26 ed with adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) and set out to eval

27 ast, 39 adenosine deaminase-deficient severe combined immunodeficiency (ADA-SCID) patients have been

28 cult' conditions [adenosine deaminase-severe combined immunodeficiency (ADA-SCID), major histocompati

29 at destroy the immune system, causing severe combined immunodeficiency (ADA-SCID), often referred to

30 order of purine metabolism leading to severe combined immunodeficiency (ADA-SCID).

31 of immune manifestations, such as late-onset combined immunodeficiency and autoimmunity.

32 ify the genetic alteration in a patient with combined immunodeficiency and characterize human caspase

33 ecessive CD70 deficiency is a novel cause of combined immunodeficiency and EBV-associated diseases, r

34 l case of an RSV-infected infant with severe combined immunodeficiency and effectively no adaptive im

35 allosal agenesis, cataracts, cardiomyopathy, combined immunodeficiency and hypopigmentation.

36 enting with a much more complex phenotype of combined immunodeficiency and immune dysregulation.

37 Mutations associated with severe combined immunodeficiency and Omenn syndrome had signifi

38 oal of defining the true incidence of severe combined immunodeficiency and providing early treatment

39 patients presented from early childhood with combined immunodeficiency and severe autoimmune disease.

40 ted disorders, including MIA associated with combined immunodeficiency and very early onset inflammat

41 y immunodeficiencies (PIDs) including severe combined immunodeficiency and Wiskott-Aldrich syndrome a

42 jected intraperitoneally (ie, in CB17 severe combined immunodeficiencies) and significantly increased

43 osa-associated lymphoid tissue 1 (MALT1) for combined immunodeficiencies, and tetratricopeptide repea

44 Background Combined immunodeficiencies are marked by inborn errors

45 Omenn syndrome (OS) is a rare severe combined immunodeficiency associated with autoimmunity a

46 y reported a novel syndrome characterized by combined immunodeficiency associated with severe develop

47 lifornia established the incidence of severe combined immunodeficiency at 1 in 66,250 live births.

48 Orai1 Ca2+ channels lead to a form of severe combined immunodeficiency, auto-immunity, muscle hypoton

49 heart) was tested in infarcted SCID (severe combined immunodeficiency)-Beige mice.

50 given intranasally or i.p. to newborn severe combined immunodeficiency-beige mice exposed to 90% O2 f

51 ridium parasites from 6 of 7 infected severe combined immunodeficiency-beige mice, and the parasites

52 t is a common finding in infants with severe combined immunodeficiency but is not typically observed

53 Janus kinase 3 (JAK3) are a cause of severe combined immunodeficiency, but hypomorphic JAK3 defects

54 overy occurred in VLP-dosed mice with severe combined immunodeficiency, but not in wild-type mice dep

55 T-cell deficiencies in patients with severe combined immunodeficiency by replacing resident thymus c

56 ed via osmotic pump in an intratibial severe combined immunodeficiency CAG myeloma model or in a syst

57 cy CAG myeloma model or in a systemic severe combined immunodeficiency CAG-heparanase model of aggres

58 Severe combined immunodeficiency can be caused by loss-of-funct

59 Profound combined immunodeficiency can present with normal number

60 tor of cytokinesis 8 (DOCK8) deficiency is a combined immunodeficiency caused by autosomal recessive

61 I3K-delta) syndrome (APDS) is a rare primary combined immunodeficiency caused by either dominant gain

62 s emerged as a convincing therapy for severe combined immunodeficiency caused by ILR2G mutation (SCID

63 n dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency characterized by atopy, recurr

64 ations in DOCK8 have been reported to have a combined immunodeficiency characterized by cutaneous vir

65 DOCK8 mutations result in an inherited combined immunodeficiency characterized by increased sus

66 ytokine receptor subunit give rise to severe combined immunodeficiency characterized by lack of T and

67 Patients with a combined immunodeficiency characterized by normal number

68 g c-Rel protein expression in a patient with combined immunodeficiency characterized by susceptibilit

69 ovirus incidence was compared between severe combined immunodeficiency children with (n = 10) and wit

70 on of disease phenotypes for X-linked severe combined immunodeficiency, chronic granulomatous disease

71 n dedicator of cytokinesis 8 (DOCK8) cause a combined immunodeficiency (CID) also classified as autos

72 Combined immunodeficiency (CID) is a T-cell defect frequ

73 Combined immunodeficiency (CID) is characterized by seve

74 Combined immunodeficiency (CID) refers to inborn errors

75 I1 and STIM1 genes that abolish SOCE cause a combined immunodeficiency (CID) syndrome that is accompa

76 onical NF-kappaBeta pathways, resulting in a combined immunodeficiency (CID) without endocrine or ect

77 truction that is sometimes associated with a combined immunodeficiency (CID), leading to increased su

78 o present with autologous circulating T-cell combined immunodeficiency (CID).

79 Combined immunodeficiencies (CIDs) and "atypical" SCID s

80 Combined immunodeficiencies (CIDs) are diseases of defec

81 Combined immunodeficiencies (CIDs) form a heterogeneous

82 this review we describe peculiarities about combined immunodeficiencies (CIDs) in the Middle East.

83 Further, the nonobese diabetic severe combined immunodeficiency common gamma chain knockout-bo

84 PNP-combined immunodeficiency complies with the criteria for

85 Newborn screening for severe combined immunodeficiency detects athymic patients, alth

86 decrease in survival and developed a severe combined immunodeficiency disease (SCID) affecting B, T,

87 The approach to the diagnosis of severe combined immunodeficiency disease (SCID) and related dis

88 ead to an autosomal recessive form of severe combined immunodeficiency disease (SCID).

89 nt with WHIM syndrome, an autosomal dominant combined immunodeficiency disease caused by gain-of-func

90 PET experiments were performed in severe combined immunodeficiency disease mice inoculated with p

91 Patients with severe combined immunodeficiency disease who have matched sibli

92 Children with clinical features of combined immunodeficiencies, especially with early-onset

93 s with specific forms of PID, such as severe combined immunodeficiency, for over 10 years.

94 s of anti-CD3epsilon mAb treatment in severe combined immunodeficiency forms characterized by poor th

95 healthy donors were injected into NOD-severe combined immunodeficiency gammac(-/-) mice, followed by

96 Nonobese diabetic-severe combined immunodeficiency-gammac(-/-) mice were injected

97 ells proliferate in nonobese diabetes/severe combined immunodeficiency/gammac(null) mice under the in

98 tients with atypical presentations of severe combined immunodeficiency gene mutations presents an opp

99 nt advances and newborn screening for severe combined immunodeficiency, has resulted in improved outc

100 ts with adenosine deaminase deficient severe combined immunodeficiency have identified neutropenia, a

101 -infected humanized nonobese diabetic severe combined immunodeficiency (HU-NOD/SCID) mice were genera

102 prevented bone destruction in vivo in severe combined immunodeficiency-hu mice.

103 Although its complete defect causes severe combined immunodeficiency (ie, T(-)B(-) severe combined

104 and engraftment in nonobese diabetic/severe combined immunodeficiency IL-2gamma(null) (NSG) mice com

105 We report here the cause of combined immunodeficiency in 4 patients from 2 different

106 We studied the molecular basis of combined immunodeficiency in a patient who presented wit

107 In 6.5 years of newborn screening for severe combined immunodeficiency in California, 3,252,156 infan

108 encoding gamma(c) results in X-linked severe combined immunodeficiency in humans, and gamma(c) family

109 in patients with MIA and MIA associated with combined immunodeficiency include abnormalities of enter

110 hosts as well as in nonobese diabetic/severe combined immunodeficiency/interleukin 2Rgamma(null) mice

111 e immune-deficient (nonobese diabetic/severe combined immunodeficiency/interleukin-2 gammac receptor(

112 efore, we created a nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-gamma-n

113 on by transplanting nonobese diabetic/severe combined immunodeficiency/interleukin-2 receptor-gamma-n

114 arly onset of bone marrow failure leading to combined immunodeficiency is associated with microcephal

115 mbined immunodeficiency (ie, T(-)B(-) severe combined immunodeficiency), its suboptimal activity is a

116 eplacement for Hemophilia B, X-linked Severe Combined Immunodeficiency, Leber's Congenital Amaurosis

117 T cells in a spectrum including leaky severe combined immunodeficiency (LS) and Omenn syndrome (OS).

118 rowth in vitro, and tumorigenicity in severe combined immunodeficiency mice (all P < 0.05).

119 lls, leading to increased survival of severe combined immunodeficiency mice after transplantation of

120 al liver cells into nonobese diabetic/severe combined immunodeficiency mice allows for the long-term

121 after subcutaneous transplantation in severe combined immunodeficiency mice and differentiated into S

122 d copper-DOTA-conatumumab was done in severe combined immunodeficiency mice bearing Colo205 xenograft

123 In female CB17 severe combined immunodeficiency mice bearing Colo205 xenograft

124 by PET and ex vivo biodistribution in severe combined immunodeficiency mice bearing H2009 tumor (huma

125 o experiments, 6- to 12-wk-old female severe combined immunodeficiency mice bearing M21 xenografts (h

126 4)-BBN: for in vivo GRPR blockade) in severe combined immunodeficiency mice bearing PC-3 xenografts.

127 n erythrocytes into nonobese diabetic/severe combined immunodeficiency mice extends blood circulation

128 s transplanted onto nonobese diabetic/severe combined immunodeficiency mice faithfully recapitulated

129 Finally, YT cells transplanted into severe combined immunodeficiency mice had an invasive behavior.

130 Six nonobese diabetic severe combined immunodeficiency mice received transplanted hum

131 ed the development of diabetes in NOD severe combined immunodeficiency mice receiving diabetogenic sp

132 transplantation in Non-obese diabetic/severe combined immunodeficiency mice that the HAGE knockdown i

133 ion in xenotolerant nonobese diabetic/severe combined immunodeficiency mice through intrasplenic or i

134 ted nonobese diabetic background with severe combined immunodeficiency mice to assess suppressive fun

135 Nonobese diabetic/severe combined immunodeficiency mice transplanted with leukemi

136 The tumorigenicity of cells in severe combined immunodeficiency mice was augmented to a larger

137 Male severe combined immunodeficiency mice were subcutaneously impla

138 nized urokinase plasminogen activator/severe combined immunodeficiency mice were used to establish ch

139 lanted with MSCs in nonobese diabetic severe combined immunodeficiency mice with a significantly high

140 mproved survival of nonobese diabetic/severe combined immunodeficiency mice with HL-60 leukemia.

141 eased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and

142 nced MM cells were then injected into severe combined immunodeficiency mice, and tumor growth in s.c.

143 In a xenograft analysis of severe combined immunodeficiency mice, cisplatin also efficient

144 as not observed in non-obese diabetic/severe combined immunodeficiency mice, indicating the immune re

145 In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of human HCC

146 immunocompromised non-obese diabetic/severe combined immunodeficiency mice, supporting an oncogenic

147 MB-231 cell-derived mammary tumors in severe combined immunodeficiency mice, we show here for the fir

148 sts and in aggressive tumor growth in severe combined immunodeficiency mice.

149 day prior to graft implantation into severe combined immunodeficiency mice.

150 s the tumorigenicity of A549 cells in severe combined immunodeficiency mice.

151 nhibited cholangiocarcinoma growth in severe combined immunodeficiency mice.

152 ro and in engrafted nonobese diabetic-severe combined immunodeficiency mice.

153 the choroids of six nude rats and six severe combined immunodeficiency mice.

154 hen transplanted to nonobese diabetic/severe combined immunodeficiency mice.

155 ansfer, delayed diabetes onset in NOD.severe combined immunodeficiency mice.

156 the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice.

157 n PBMC cultures and in PBMC-engrafted severe combined immunodeficiency mice.

158 the skeletal muscle of dystrophic mdx/severe combined immunodeficiency mice.

159 agar assays and xenograft analysis of severe combined immunodeficiency mice.

160 -L1-negative, and mixed tumor-bearing severe combined immunodeficiency mice.

161 1 nu/nu and LNCaP tumor-bearing CB-17 severe combined immunodeficiency mice.

162 suppressed tumor xenograft growth in severe combined immunodeficiency mice.

163 subcutaneously into nonobese diabetic severe combined immunodeficiency mice.

164 SCID (severe combined immunodeficiency) mice underwent left anterior

165 When xenografted into SCID (severe combined immunodeficiency) mice, the expression of muPAR

166 found in NOD/SCID (non-obese diabetic/severe combined immunodeficiency) mice.

167 In human artery-severe combined immunodeficiency mouse chimeras, in which patie

168 ation into diabetic nonobese diabetic-severe combined immunodeficiency mouse kidneys.

169 lence in human skin xenografts in the severe combined immunodeficiency mouse model in vivo.

170 ly in infected skin xenografts in the severe combined immunodeficiency mouse model of VZV pathogenesi

171 Using a nonobese diabetic/severe combined immunodeficiency mouse model, those antibodies

172 ftment in NOD-SCID (nonobese diabetic-severe combined immunodeficiency) mouse myocardium increased ca

173 h experimental systemic infections of severe combined immunodeficiency Mus musculus with the bacteriu

174 ith a synthetic LAT gene bearing this severe combined immunodeficiency mutation.

175 cell lymphopenic infants had variant SCID or combined immunodeficiency (n = 6), genetic syndromes ass

176 he renal capsule of nonobese diabetic severe combined immunodeficiency (NOD SCID) mice with MSCs isol

177 +) progenitors into nonobese diabetic/severe combined immunodeficiency (NOD-SCID) mice resulted in th

178 xpressing tumors in nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice with partially

179 induced diabetes in nonobese diabetic severe combined immunodeficiency (NOD/SCID) mice.

180 il dystrophy, accounting for the nude/severe combined immunodeficiency (nu/SCID) phenotype in humans

181 entified in patients and are associated with combined immunodeficiencies of varying severity.

182 ided into 3 main categories: T(-)B(-) severe combined immunodeficiency, Omenn syndrome, and combined

183 been reported to be associated with either a combined immunodeficiency or common variable immunodefic

184 uses T(-)B(+) natural killer-positive severe combined immunodeficiency or T-cell lymphopenia with sev

185 ystem since it did not occur in nude, severe combined immunodeficiency, or T-cell depleted mice.

186 ons or autoimmunity, they represent profound combined immunodeficiency (P-CID), for which outcome dat

187 xpression of Bcl2 does not rescue the severe combined immunodeficiency phenotype in Ku70-deficient mi

188 We describe a pedigree affected by a severe combined immunodeficiency phenotype with absent T cells

189 lex are now recognized as the cause of novel combined immunodeficiency phenotypes, which all share ab

190 A 14-year-old boy with severe combined immunodeficiency presented three times to a med

191 of STAT1 can be associated with progressive combined immunodeficiency, quite distinct from the limit

192 eficiency presents with a varied spectrum of combined immunodeficiency, ranging from a T(-)B(-)NK(+)

193 ular, and clinical features of many types of combined immunodeficiencies remain unknown.

194 ntains a rare CD34(-) population with severe combined immunodeficiency-repopulating capacity.

195 ectasia and a class of Radiosensitive-Severe Combined Immunodeficiency (RS-SCID), respectively, funct

196 n therefore results in radiosensitive severe combined immunodeficiency (RS-SCID).

197 -lymphocyte-independent protection of severe combined immunodeficiency SCID mice from disseminated ca

198 A subgroup of severe combined immunodeficiencies (SCID) is characterized by l

199 , wild-type (WT) and C3H animals with severe combined immunodeficiency (SCID animals) were inoculated

200 on of adenosine deaminase (ADA) cause severe combined immunodeficiency (SCID) and affect many other c

201 TEMIS deficiency usually present with severe combined immunodeficiency (SCID) and cellular radiosensi

202 cell transplantation in children with severe combined immunodeficiency (SCID) and other primary immun

203 opulation-based newborn screening for severe combined immunodeficiency (SCID) and related disorders h

204 Severe combined immunodeficiency (SCID) and X-linked agammaglob

205 Severe combined immunodeficiency (SCID) arises from different g

206 Severe combined immunodeficiency (SCID) can be cured by using a

207 e show that over 90% of patients with severe combined immunodeficiency (SCID) can be genetically-char

208 Severe combined immunodeficiency (SCID) carries a poor prognosi

209 g gene 1 (RAG1) deficiency results in severe combined immunodeficiency (SCID) caused by a complete la

210 Severe combined immunodeficiency (SCID) comprises a group of di

211 Severe combined immunodeficiency (SCID) comprises a heterogeneo

212 pathology of Omenn syndrome and leaky severe combined immunodeficiency (SCID) has not been previously

213 The inclusion of severe combined immunodeficiency (SCID) in a Europe-wide screen

214 cular dysgenesis (RD), a rare form of severe combined immunodeficiency (SCID) in humans.

215 Severe combined immunodeficiency (SCID) is a life-threatening d

216 Early recognition of severe combined immunodeficiency (SCID) is a pediatric emergenc

217 Adenosine deaminase (ADA)-severe combined immunodeficiency (SCID) is caused by genetic va

218 Severe combined immunodeficiency (SCID) is characterized by arr

219 Severe combined immunodeficiency (SCID) is characterized by sev

220 ne deaminase (ADA) cause a subtype of severe combined immunodeficiency (SCID) known as severe combine

221 was determined in LNCaP tumor-bearing severe combined immunodeficiency (SCID) mice after sacrifice at

222 essing SDF-1alpha were xenografted on severe combined immunodeficiency (SCID) mice.

223 oft agar and enhanced tumor growth in severe combined immunodeficiency (SCID) mice.

224 by transfer of their splenocytes into severe combined immunodeficiency (SCID) mice.

225 phagy in human skin xenografts in the severe combined immunodeficiency (SCID) mouse model of VZV path

226 RARalpha2-overexpressing MM tumors in severe combined immunodeficiency (SCID) mouse model.

227 at least a month in both nude rat and severe combined immunodeficiency (SCID) mouse xenograft models

228 onobese diabetic (NOD) mice, NOD with severe combined immunodeficiency (scid) mutation (SCID) mice, a

229 iver cells in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) or NOD/SCID/gammac(-/-)

230 nonimmunologic outcomes in cohorts of severe combined immunodeficiency (SCID) patients with either RA

231 Severe combined immunodeficiency (SCID) represents congenital d

232 Severe combined immunodeficiency (SCID) represents the most let

233 sis is an autosomal recessive form of severe combined immunodeficiency (SCID) that usually manifests

234 um (PIDTC) is enrolling children with severe combined immunodeficiency (SCID) to a prospective natura

235 Newborn screening for severe combined immunodeficiency (SCID) using assays to detect

236 Severe combined immunodeficiency (SCID) with a complete absence

237 that impair Rag2 function can lead to severe combined immunodeficiency (SCID), a condition characteri

238 position found in some patients with severe combined immunodeficiency (SCID), and the double mutant

239 l reconstitution in many infants with severe combined immunodeficiency (SCID), but correction of B-ce

240 een identified, often associated with severe combined immunodeficiency (SCID), consistent with the re

241 to young horses (foals) affected with severe combined immunodeficiency (SCID), followed by challenge

242 cal profound T-cell dysfunction (TD), severe combined immunodeficiency (SCID), has been carefully def

243 vical spinal cords of adult mice with severe combined immunodeficiency (SCID), human pluripotent stem

244 ansplantation (HCT) for patients with severe combined immunodeficiency (SCID), including survival, T-

245 evant per se because in patients with severe combined immunodeficiency (SCID), infections caused by o

246 (ADA) deficiency, a cause of X-linked severe combined immunodeficiency (SCID), is a case in point.

247 und primary immunodeficiency disease, severe combined immunodeficiency (SCID), is fatal in infancy un

248 The most severe form, severe combined immunodeficiency (SCID), presents with profound

249 tural history of patients treated for severe combined immunodeficiency (SCID), Wiskott-Aldrich syndro

250 te lymphocyte development and lead to severe combined immunodeficiency (SCID), XLF mutations cause a

251 In a severe combined immunodeficiency (SCID)-hu murine model of huma

252 in ORAI1 or STIM1 genes present with severe combined immunodeficiency (SCID)-like disease.

253 pathway result in radiation-sensitive severe combined immunodeficiency (SCID).

254 G) xenografts maintained in mice with severe combined immunodeficiency (SCID).

255 ion-based newborn screening (NBS) for severe combined immunodeficiency (SCID).

256 abesia microti infection in mice with severe combined immunodeficiency (SCID).

257 f adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

258 nation, hence loss of DNA-PK leads to severe combined immunodeficiency (SCID).

259 e plasma in young horses (foals) with severe combined immunodeficiency (SCID).

260 gnificant proportion of patients with severe combined immunodeficiency (SCID).

261 ansplantation (HSCT) in patients with severe combined immunodeficiency (SCID).

262 n-2 gamma-chain receptor (IL2RG)/JAK3 severe combined immunodeficiency (SCID).

263 ic metabolic disease characterized by severe combined immunodeficiency (SCID).

264 the generation of a marmoset model of severe combined immunodeficiency (SCID).

265 B-lymphocytes and are diagnosed with severe combined immunodeficiency (SCID).

266 rabian and 1 Arabian-pony cross) with severe combined immunodeficiency (SCID).

267 development, clinically presenting as severe combined immunodeficiency (SCID).

268 immunodeficiencies including X-linked severe combined immunodeficiency (SCID-X1) and adenine deaminas

269 X-linked severe combined immunodeficiency (SCID-X1) caused by mutations

270 X-linked severe-combined immunodeficiency (SCID-X1) has been treated by

271 X-linked Severe Combined Immunodeficiency (SCID-X1) is a genetic disease

272 tem-cell transplantation for X-linked severe combined immunodeficiency (SCID-X1) often fails to recon

273 ials involving children with X-linked severe combined immunodeficiency (SCID-X1), a Moloney murine le

274 vectors for gene therapy of X-linked severe combined immunodeficiency (SCID-X1), we have evaluated n

275 for the correction of canine X-linked severe combined immunodeficiency (SCID-X1).

276 hy donors and a subject with X-linked severe combined immunodeficiency (SCID-X1).

277 use in a clinical trial for X-linked severe combined immunodeficiency (SCID-X1).

278 in vivo in hairless outbred mice with severe combined immunodeficiency (SHO-Prkdc(scid)Hr(hr)).

279 phopenia, patients with ADA-deficient severe combined immunodeficiency showed a partial block in cent

280 nically mild initial presentation could be a combined immunodeficiency, so as to provide appropriate

281 A patient with multiorgan autoinflammation, combined immunodeficiency, subclinical amylopectinosis,

282 that inactivate Artemis cause a human severe combined immunodeficiency syndrome associated with cellu

283 mutations are responsible for a rare primary combined immunodeficiency syndrome associated with sever

284 inflammation, muscle weakness, and a severe combined immunodeficiency syndrome.

285 ast, hypomorphic Artemis mutations result in combined immunodeficiency syndromes of varying severity,

286 shed tumors (ie, in nonobese diabetic-severe combined immunodeficiencies) that were derived from CD44

287 a spectrum of phenotypes ranging from severe combined immunodeficiency to immune dysregulation.

288 We performed a multicenter survey of severe combined immunodeficiency transplantation centers in Nor

289 h adenosine deaminase (ADA)-deficient severe combined immunodeficiency using 2 slightly different ret

290 ntified through newborn screening for severe combined immunodeficiency using the T-cell receptor exci

291 neutrophil infiltration in mice with severe combined immunodeficiency, which is accompanied by stron

292 Most defects lead to combined immunodeficiency with a range of severity.

293 in AK2 cause reticular dysgenesis, a severe combined immunodeficiency with agranulocytosis, lymphope

294 ciency should be considered in patients with combined immunodeficiency with B cell, T cell, and fibro

295 ntified in patients with a recessive form of combined immunodeficiency with defects in T, B, and NK c

296 Combined immunodeficiency with multiple intestinal atres

297 ciency should be considered in patients with combined immunodeficiency with T-cell abnormalities.

298 e bone marrow transplant for X-linked severe combined immunodeficiency, with no recovery of T lymphoc

299 n complex 1B (ARPC1B) subunit of Arp2/3 show combined immunodeficiency, with symptoms of immune dysre

300 X-linked severe combined immunodeficiency (X-SCID) is an immune disorder